{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:26Z","timestamp":1793998046553,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Leukemia Net"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41375-024-02183-0","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T03:01:55Z","timestamp":1708657315000},"page":"788-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-1789","authenticated-orcid":false,"given":"Ekaterina","family":"Chelysheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-1794","authenticated-orcid":false,"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2371","authenticated-orcid":false,"given":"Anna","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Barraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khamida","family":"Kazakbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhrob","family":"Saliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi Shacham","family":"Abulafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-5748","authenticated-orcid":false,"given":"Salam","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry F.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-1002","authenticated-orcid":false,"given":"Roman","family":"Shmakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Polushkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"de Fabritiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata Monika","family":"Trawinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2183_CR1","doi-asserted-by":"crossref","unstructured":"Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council\u2019s working party for therapeutic trials in leukaemia. Br Med J. 1968;1:201\u20138","DOI":"10.1136\/bmj.1.5586.201"},{"key":"2183_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/10428194.2016.1201571","volume":"58","author":"AD Law","year":"2017","unstructured":"Law AD, Kim DDH, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. Leuk Lymphoma. 2017;58:280\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2183_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/hematology.2022000330","volume":"2022","author":"HF Robertson","year":"2022","unstructured":"Robertson HF, Apperley JF. Treatment of CML in pregnancy. Hematol Am Soc Hematol Educ Program. 2022;2022:123\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2183_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966120","volume":"11","author":"E Abruzzese","year":"2020","unstructured":"Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020;11:2040620720966120.","journal-title":"Ther Adv Hematol"},{"key":"2183_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/ejh.13215","volume":"102","author":"E Chelysheva","year":"2019","unstructured":"Chelysheva E, Turkina A. Risks and challenges of CML management during pregnancy: looking for a balanced decision. Eur J Hematol. 2019;102:378\u20139.","journal-title":"Eur J Hematol"},{"key":"2183_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-022-00686-0","volume":"18","author":"E Berdman","year":"2023","unstructured":"Berdman E. Family planning and pregnancy in patients with chronic myeloid leukemia. Curr Hematol Malignancy Rep. 2023;18:1\u20137.","journal-title":"Curr Hematol Malignancy Rep"},{"key":"2183_CR7","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505\u20138.","journal-title":"Blood"},{"key":"2183_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111\u20135.","journal-title":"Am J Hematol"},{"key":"2183_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"E Abruzzese","year":"2016","unstructured":"Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9:781\u201391.","journal-title":"Expert Rev Hematol"},{"key":"2183_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","volume":"9","author":"S Cole","year":"2009","unstructured":"Cole S, Kantarjian H, Ault P, Cort\u00e9s JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9:324\u20137.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2183_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","volume":"55","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Ali Z, Khan AU, Aziz Z. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014;55:2109\u201313.","journal-title":"Leuk Lymphoma"},{"key":"2183_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/annonc\/mdv172","volume":"26","author":"C Jovelet","year":"2015","unstructured":"Jovelet C, Seck A, Mir O, Simasotchi C, Broutin S, Goffinet F, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol. 2015;26:1500\u20134.","journal-title":"Ann Oncol"},{"key":"2183_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","volume":"59","author":"E Chelysheva","year":"2018","unstructured":"Chelysheva E, Turkina A, Polushkina E, Shmakov R, Zeifman A, Aleshin S, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma. 2018;59:733\u20138.","journal-title":"Leuk Lymphoma"},{"key":"2183_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russell","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2007;27:241\u20133.","journal-title":"J Perinatol"},{"key":"2183_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/jcm11071801","volume":"11","author":"E Abruzzese","year":"2022","unstructured":"Abruzzese E, Aureli S, Bondanini F, Ciccarone M, Cortis E, Di Paolo A, et al. Chronic myeloid leukemia and pregnancy: when dreams meet reality. State of the art, management and outcome of 41 cases, nilotinib placental transfer. J Clin Med. 2022;11:1801.","journal-title":"J Clin Med"},{"key":"2183_CR16","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2020-0004","volume":"9","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, De Annuntis L, Br\u00fcmmendorf TH. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol. 2020;9:IJH26.","journal-title":"Int J Hematol Oncol"},{"key":"2183_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","volume":"39","author":"H Alizadeh","year":"2015","unstructured":"Alizadeh H, Jaafar H, Rajnics P, Khan MI, Kajt\u00e1r B. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015;39:47\u201351.","journal-title":"Leuk Res"},{"key":"2183_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","volume":"23","author":"P Berveiller","year":"2012","unstructured":"Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012;23:754\u20137.","journal-title":"Anticancer Drugs"},{"key":"2183_CR19","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","volume":"60","author":"M Lasica","year":"2019","unstructured":"Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma. 2019;60:1796\u2013802.","journal-title":"Leuk Lymphoma"},{"key":"2183_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1034\/j.1600-0412.2000.079009803.x","volume":"79","author":"M Celiloglu","year":"2000","unstructured":"Celiloglu M, Altunyurt S, Undar B. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Acta Obstet Gynecol Scand. 2000;79:803\u20134.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2183_CR21","doi-asserted-by":"publisher","first-page":"e2019040","DOI":"10.4084\/mjhid.2019.040","volume":"11","author":"D Jain","year":"2019","unstructured":"Jain D, Atmapoojya P, Colah R, Lodha P. Sickle cell disease and pregnancy. Mediterr J Hematol Infect Dis. 2019;11:e2019040.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2183_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12288-015-0519-0","volume":"32","author":"M Rohilla","year":"2016","unstructured":"Rohilla M, Rai R, Yanamandra U, Chaudhary N, Malhotra P, Varma N, et al. Obstetric complications and management in chronic myeloid leukemia. Indian J Hematol Blood Transfus. 2016;32:62\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2183_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2183_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/10428194.2020.1849672","volume":"62","author":"R Assi","year":"2021","unstructured":"Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021;62:909\u201317.","journal-title":"Leuk Lymphoma"},{"key":"2183_CR25","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3324\/haematol.2018.214809","volume":"104","author":"S Claudiani","year":"2019","unstructured":"Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, et al. MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica. 2019;104:2206\u201314.","journal-title":"Haematologica"},{"key":"2183_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia"},{"key":"2183_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","volume":"280","author":"R Ali","year":"2009","unstructured":"Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280:169\u201375.","journal-title":"Arch Gynecol Obstet"},{"key":"2183_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/AOG.0000000000001972","volume":"129","author":"RM Burwick","year":"2017","unstructured":"Burwick RM, Kuo K, Brewer D, Druker BJ. Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. Obstet Gynecol. 2017;129:831\u20134.","journal-title":"Obstet Gynecol"},{"key":"2183_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pedneo.2014.03.010","volume":"56","author":"A Egbe","year":"2015","unstructured":"Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol. 2015;56:25\u201330.","journal-title":"Pediatr Neonatol"},{"key":"2183_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.86","volume":"2","author":"S Homma","year":"2016","unstructured":"Homma S, Mess\u00e9 SR, Rundek T, Sun YP, Franke J, Davidson K, et al. Patent foramen ovale. Nat Rev Dis Prim. 2016;2:15086.","journal-title":"Nat Rev Dis Prim"},{"key":"2183_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00403-020-02147-1","volume":"313","author":"R Tripathi","year":"2021","unstructured":"Tripathi R, Mazmudar RS, Knusel KD, Ezaldein HH, Belazarian LT, Bordeaux JS, et al. Impact of congenital cutaneous hemangiomas on newborn care in the United States. Arch Dermatol Res. 2021;313:641\u201351.","journal-title":"Arch Dermatol Res"},{"key":"2183_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/uog.17347","volume":"49","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. International estimated fetal weight standards of the INTERGROWTH-21st Project. Ultrasound Obstet Gynecol. 2017;49:478\u201386.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2183_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ogc.2021.02.002","volume":"48","author":"SE Damhuis","year":"2021","unstructured":"Damhuis SE, Ganzevoort W, Gordijn SJ. Abnormal fetal growth: small for gestational age, fetal growth restriction, large for gestational age: definitions and epidemiology. Obstet Gynecol Clin N Am. 2021;48:267\u201379.","journal-title":"Obstet Gynecol Clin N Am"},{"key":"2183_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-0609.2005.00420.x","volume":"74","author":"S Al Kindi","year":"2005","unstructured":"Al Kindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol. 2005;74:535\u20137.","journal-title":"Eur J Haematol"},{"key":"2183_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1471-0528.1983.tb08911.x","volume":"90","author":"SL Barron","year":"1983","unstructured":"Barron SL. Birthweight and ethnicity. Br J Obstet Gynaecol. 1983;90:289\u201390.","journal-title":"Br J Obstet Gynaecol"},{"key":"2183_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ppe.12608","volume":"33","author":"ML Urquia","year":"2019","unstructured":"Urquia ML. Variability in birthweight, birthweight charts, and adverse outcomes: Is the \u201cright size\u201d the right question? Paediatr Perinat Epidemiol. 2019;33:433\u20135.","journal-title":"Paediatr Perinat Epidemiol"},{"key":"2183_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00404-017-4341-9","volume":"295","author":"LM Nardozza","year":"2017","unstructured":"Nardozza LM, Caetano AC, Zamarian AC, Mazzola JB, Silva CP, Mar\u00e7al VM, et al. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017;295:1061\u201377.","journal-title":"Arch Gynecol Obstet"},{"key":"2183_CR38","first-page":"332","volume":"6","author":"A Romo","year":"2009","unstructured":"Romo A, Carceller R, Tobajas J. Intrauterine growth retardation (IUGR): epidemiology and etiology. Pediatr Endocrinol Rev. 2009;6:332\u20136.","journal-title":"Pediatr Endocrinol Rev"},{"key":"2183_CR39","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","volume":"84","author":"R Hehlmann","year":"1994","unstructured":"Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064\u201377.","journal-title":"Blood"},{"key":"2183_CR40","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398\u2013406.","journal-title":"Leukemia"},{"key":"2183_CR41","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2183_CR42","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2183_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. EuropeanLeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2183_CR44","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","volume":"117","author":"WA Wood","year":"2011","unstructured":"Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood. 2011;117:5803\u201315.","journal-title":"Blood"},{"key":"2183_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000363434","volume":"132","author":"N Pemmaraju","year":"2014","unstructured":"Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132:298\u2013306.","journal-title":"Acta Haematol"},{"key":"2183_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M, Proetel U, M\u00fcller MC, Hanfstein B, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93:71\u201380.","journal-title":"Ann Hematol"},{"key":"2183_CR47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/trf.14448","volume":"58","author":"EM Staley","year":"2018","unstructured":"Staley EM, Simmons SC, Feldman AZ, Lorenz RG, Marques MB, Williams LA 3rd, et al. Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapheresis appropriate? A case report and review of the literature. Transfusion. 2018;58:456\u201360.","journal-title":"Transfusion"},{"key":"2183_CR48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ajh.26067","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Tefferi A. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. Am J Hematol. 2021;96:354\u201366.","journal-title":"Am J Hematol"},{"key":"2183_CR49","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","volume":"94","author":"M Talpaz","year":"2015","unstructured":"Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94:S195\u2013207.","journal-title":"Ann Hematol"},{"key":"2183_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ajh.9876","volume":"69","author":"AA Mubarak","year":"2002","unstructured":"Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002;69:115\u20138.","journal-title":"Am J Hematol"},{"key":"2183_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","volume":"82","author":"HM Kantarjian","year":"1993","unstructured":"Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691\u2013703.","journal-title":"Blood"},{"key":"2183_CR52","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1055\/s-2006-942761","volume":"32","author":"A Quinta\u00b4s-Cardama","year":"2006","unstructured":"Quinta\u00b4s-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Thromb Hemost. 2006;32:409\u201316.","journal-title":"Thromb Hemost"},{"key":"2183_CR53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","volume":"33","author":"G Varyt\u0117","year":"2021","unstructured":"Varyt\u0117 G, Arlauskien\u0117 A, Rama\u0161auskait\u0117 D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33:378\u201383.","journal-title":"Curr Opin Obstet Gynecol"}],"updated-by":[{"DOI":"10.1038\/s41375-024-02412-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02183-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02183-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:22:48Z","timestamp":1726744968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02183-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02183-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-024-02412-6","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-024-02412-6","URL":"https:\/\/doi.org\/10.1038\/s41375-024-02412-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EC \u2013 speaker: Novartis, Pfizer, R-Pharm, consultancy: Ascentage Pharma, JA \u2013 speaker: Novartis, Bristol Myers Squibb, Incyte, honoraria: Novartis, Bristol Myers Squibb, Incyte, Research Funding: Pfizer, Incyte, AT \u2013 speaker: Novartis, Pfizer, R-Pharm, Amgen, consultancy\/advisory board: Novartis, DR \u2013 Novartis, Incyte, Pfizer, Terns, FEN \u2013 consultancy: Sun Pharma Ltd, Novartis, speaker: Incyte Biosciences, board entity: Incyte Biosciences, Pfizer, Novartis, BMS-Celgene, research fundings: Incyte Biosciences, Novartis, ASA \u2013 consultancy: Novartis, JB \u2013 honoraria: Novartis, Incyte, Pfizer, MC \u2013 advisory board: Insight, Novartis, Italfarmaco, speaker: Servier, Abbvie, Janssen, PF \u2013 consultancy: Jazz, Jannsen, Abbvie, MMT \u2013 consultancy: Novartis, Takeda, EA \u2013 consultancy: BMS, Novaris, Incyte, Pfizer, advisory: BMS, Novaris, Incyte, Pfizer, SAK, MAY, DB, KhK, SS, HFR, RS and EP \u2013 nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}